T14.SI up 8.84% to S$3.20 AH 05 Feb 2026: Da Ren Tang (SES) volume surge

T14.SI stock jumped 8.84% to S$3.20 in after-hours trading on 05 Feb 2026, driven by a volume print of 407,000 shares, roughly 1.78x the average. The spike follows a session high of S$3.21 and marks a move above the 200-day average of S$2.81. Traders flagged the surge as a high-volume mover on the Singapore Exchange (SES), drawing attention to valuation and dividend signals.

Price action and high-volume context for T14.SI stock

T14.SI stock closed the regular session at S$2.94 and rose to S$3.20 after hours, a S$0.26 gain or 8.84%. Volume for the move was 407,000, versus an average of 161,214, giving a relative volume of 1.78. The one-day range was S$3.05–S$3.21 and the 52-week range is **S$1.99–S$3.50.

High volume on an upward gap typically signals active repositioning by institutions. Given the spike and the stock’s year-to-date performance, short-term traders will watch whether the price holds above the 200-day average (S$2.81) and the 50-day average (S$3.25).

Valuation and financials: why T14.SI stock looks cheap by multiples

Tianjin Pharmaceutical Da Ren Tang Group (T14.SI) trades at PE 4.54 on an EPS of S$0.67. Price-to-book is 1.80 with book value per share at S$11.72. Market cap is about S$4.57B and shares outstanding are 1,503,367,073.

Key balance-sheet strengths include a current ratio of 2.81, negligible debt-to-equity of 0.00, and cash per share of S$2.25. The firm’s return on equity is 42.25%, and net margin sits at 66.72%, highlighting strong profitability against the Healthcare sector average. Dividend metrics show dividend per share S$3.66 and a modelled dividend yield figure that requires yield-context checks given payout ratios.

Technical signals and momentum for T14.SI stock

Technicals show an RSI of 56.51, an ADX of 30.21, and MACD near neutral (MACD 0.05, signal 0.07). Bollinger Bands sit at Upper 3.53 / Middle 3.34 / Lower 3.15. The stock traded above its 200-day MA and is near the 50-day MA.

On balance, momentum is moderate. The ADX indicates a strong underlying trend, while RSI and MACD do not show overbought extremes. Traders may watch the S$3.34–3.53 band for resistance and S$2.81 for structural support.

Meyka AI rates T14.SI with a score out of 100 and forecast

Meyka AI rates T14.SI with a score of 70.22 out of 100 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 1-year target of S$3.78, a quarterly target of S$3.75, and a 3-year target of S$5.26. Versus the current price S$3.20, the 1-year projection implies an ~18.01% upside. Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context for T14.SI stock

Catalysts include dividend announcements, hospital operations updates, and continued gross margin strength in both Chinese and western medicine lines. The Healthcare sector on SES showed modest YTD movement and average PE around 22.08, leaving T14.SI cheap by that comparison.

Risks include slower revenue growth (FY revenue growth was -11.14%), inventory cycles with days of inventory 239.31, and regulatory or distribution shifts in China. Large dividend per-share figures merit scrutiny for sustainability given cash flow metrics.

Trading strategy and price targets for T14.SI stock

For momentum traders, a near-term price target is S$3.75 (quarterly forecast) with a stop below S$3.05 (daily low). For investors, Meyka AI’s 1-year target S$3.78 implies ~18.01% upside; a conservative 3-year target is S$5.26.

Position sizing should reflect liquidity: average volume 161,214 shares, recent trade at 407,000. Use a layered buy approach on pullbacks to S$3.05–S$2.81 and monitor earnings and dividend updates.

Final Thoughts

T14.SI stock delivered a clear high-volume move after hours on 05 Feb 2026, rising 8.84% to S$3.20 on 407,000 shares. Valuation looks attractive versus sector peers, with PE 4.54 and PB 1.80, while profitability metrics such as ROE 42.25% and net margin 66.72% remain supportive. Meyka AI rates the stock 70.22/100 (B+, BUY) and projects a 1-year target of S$3.78, implying about 18.01% upside from the current price. Traders should treat the after-hours volume spike as a signal to monitor follow-through at intra-day highs and key moving averages. Investors should weigh dividend signals, cash flow coverage, and China-specific operational risks. Forecasts are model-based projections and not guarantees; continue to monitor earnings releases and sector movement on the SES

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.